SG11202104166QA - High concentration protein formulation - Google Patents

High concentration protein formulation

Info

Publication number
SG11202104166QA
SG11202104166QA SG11202104166QA SG11202104166QA SG11202104166QA SG 11202104166Q A SG11202104166Q A SG 11202104166QA SG 11202104166Q A SG11202104166Q A SG 11202104166QA SG 11202104166Q A SG11202104166Q A SG 11202104166QA SG 11202104166Q A SG11202104166Q A SG 11202104166QA
Authority
SG
Singapore
Prior art keywords
high concentration
protein formulation
concentration protein
formulation
protein
Prior art date
Application number
SG11202104166QA
Other languages
English (en)
Inventor
Hunter Chen
Erica Schlesinger
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202104166QA publication Critical patent/SG11202104166QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
SG11202104166QA 2018-11-21 2019-11-21 High concentration protein formulation SG11202104166QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770337P 2018-11-21 2018-11-21
PCT/US2019/062596 WO2020106948A1 (en) 2018-11-21 2019-11-21 High concentration protein formulation

Publications (1)

Publication Number Publication Date
SG11202104166QA true SG11202104166QA (en) 2021-05-28

Family

ID=68916589

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104166QA SG11202104166QA (en) 2018-11-21 2019-11-21 High concentration protein formulation

Country Status (13)

Country Link
US (1) US20200155678A1 (pt)
EP (1) EP3883542A1 (pt)
JP (1) JP2022532965A (pt)
KR (1) KR20210093976A (pt)
CN (1) CN113164378A (pt)
AU (1) AU2019384160A1 (pt)
BR (1) BR112021009463A2 (pt)
CA (1) CA3118306A1 (pt)
EA (1) EA202191403A1 (pt)
IL (1) IL283229A (pt)
MX (1) MX2021005910A (pt)
SG (1) SG11202104166QA (pt)
WO (1) WO2020106948A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217927A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CA2829629A1 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
CN103356490A (zh) * 2012-03-29 2013-10-23 复旦大学 可直接固体化的交联食物蛋白稳定化纳米给药系统
SG11201407512VA (en) * 2012-05-18 2014-12-30 Genentech Inc High-concentration monoclonal antibody formulations
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP3043774B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
DK2942050T3 (da) * 2014-05-06 2022-11-21 S I I T S R L Servizio Int Imballaggi Termosaldanti Spraybar, olieholdig sammensætning baseret på fedtopløselige vitaminer fra gruppe d og anvendelse deraf
EP3240571A4 (en) * 2014-12-31 2018-06-13 NovelMed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies

Also Published As

Publication number Publication date
AU2019384160A1 (en) 2021-05-27
EP3883542A1 (en) 2021-09-29
JP2022532965A (ja) 2022-07-21
IL283229A (en) 2021-07-29
CA3118306A1 (en) 2020-05-28
MX2021005910A (es) 2021-08-16
EA202191403A1 (ru) 2021-08-09
WO2020106948A1 (en) 2020-05-28
KR20210093976A (ko) 2021-07-28
BR112021009463A2 (pt) 2021-08-10
CN113164378A (zh) 2021-07-23
US20200155678A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
SG11202003754YA (en) High concentration protein formulations with reduced viscosity
EP3268050A4 (en) Pore-forming protein conjugate compositions and methods
IL282617A (en) Aerosol formulation
GB201801614D0 (en) Formulation
DK3737402T3 (en) Modificeret protein
IL281717A (en) Antibody formulation
IL282523A (en) Aerosol formulation
IL258570A (en) Stable protein preparations
IL282813A (en) Formulation of antibodies
IL282589A (en) Aerosol formulation
IL282567A (en) Aerosol formulation
IL282461A (en) Aerosol formulation
IL279895A (en) High concentration liquid antibody formulations
IL282697A (en) Aerosol formulation
IL282392A (en) Aerosol formulation
GB201816447D0 (en) Formulation
IL283229A (en) High concentration protein formulation
ZA202007491B (en) Stable fusion protein formulation
ZA201708173B (en) High concentration formulation
ZA202006263B (en) Antibody formulation
SI3731872T1 (sl) Postopek za zagotavljanje sestavka PEGiliranih beljakovin
GB201807312D0 (en) Formulation
IL280138A (en) Spray formulation
GB201813229D0 (en) Formulation
EP3522881A4 (en) HIGHLY MOBILE GROUP B1 PROTEIN INHIBITORS